Join us Dec. 1-3 in Nashville for the Digiday Programmatic Marketing Summit
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Future of Marketing Briefing: Consulting firms revive their marketing ambitions in the C-suite the holdcos covet
Consulting giants Deloitte Digital and Accenture Song have started selling marketing in the C-suite with a fresh push.
Anthropic says no to ads but Wall Street may have other ideas
With shareholders, an $895 billion compute bill and a costly free tier, Anthropic’s no-ads pledge may have a shelf life.
Why more brands are paying creators to make their ads
Creator-led production is the fastest-growing segment of the influencer economy. We explain what’s driving investment in this practice.